Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.36%
1,096.72
+3.98
+0.36%
—1,092.741,095.951,103.321,094.72——
SIXC
Communications
SIXC
Communications
SIXC
-0.33%
611.32
-2.04
-0.33%
—613.36613.36613.36609.50——
SIXE
Energy
SIXE
Energy
SIXE
-0.45%
1,171.54
-5.25
-0.45%
—1,176.791,176.521,182.251,166.69——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.45%
1,747.63
-7.91
-0.45%
—1,755.541,759.231,766.301,746.04——
SIXM
Financials
SIXM
Financials
SIXM
-0.58%
631.49
-3.66
-0.58%
—635.15635.20636.89630.09——
SIXR
Staples
SIXR
Staples
SIXR
+0.23%
849.94
+1.93
+0.23%
—848.01852.52855.78849.58——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.09%
218.06
+0.20
+0.09%
—217.86217.86219.52217.86——
SIXT
Technology
SIXT
Technology
SIXT
+3.47%
3,536.03
+118.68
+3.47%
—3,417.353,452.773,536.033,450.39——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.91%
905.07
-8.29
-0.91%
—913.36915.10920.43904.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.86%
1,449.86
-12.52
-0.86%
—1,462.381,461.131,464.531,446.02——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.30%
2,430.47
+7.33
+0.30%
—2,423.142,428.712,448.692,424.63——
Q1 2026 earnings • released • EPS miss -10.94% • Revenue miss -13.89%
See results
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$26.12
-0.04%
(-0.0100) 1D
$25.60
-1.99% (-0.52)
After hours
Closed: May 8, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
$26.05
High
$26.67
Low
$25.93
Mkt. cap
2.57B
Avg. vol.
1.87M
Volume
1.56M
52-wk high
$42.37
52-wk low
$18.29
EPS
-$6.10
Beta
0.39
Shares outstanding
98.49M
No. of employees
1K
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorBiotechnology
Websiteultragenyx.com
Last report
May 5, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
-$1.54 / -$1.39
-10.94%miss
Revenue / Est. (USD)
136.00M / 157.93M
-13.89%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
166.50M
159.93M
207.28M
136.00M
Cost of goods sold
187.74M
244.20M
232.62M
173.00M
Cost of revenue
187.74M
244.20M
232.62M
173.00M
Research and development expenses
-
-
-
16.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
86.65M
86.62M
87.94M
86.00M
Operating expense
86.65M
86.62M
87.94M
102.00M
Total operating expenses
274.38M
330.82M
320.56M
275.00M
Operating income
-107.89M
-170.89M
-113.28M
-139.00M
Other non operating income
2.14M
-1.04M
-934.00K
-
EBT including unusual items
-114.00M
-179.54M
-127.69M
-184.00M
EBT excluding unusual items
-114.00M
-180.22M
-127.17M
-154.00M
Income tax expense
947.00K
873.00K
870.00K
1.00M
Effective tax rate
-0.83%
-0.49%
-0.68%
-0.54%
Other operating expenses
-
-
-
-
Net income
-114.95M
-180.41M
-128.56M
-185.00M
Net profit margin
-69.04%
-112.81%
-62.02%
-136.03%
Earnings per share
-1.17
-1.81
-1.29
-1.54
Interest and investment income
5.79M
5.86M
6.51M
6.00M
Interest expense
-14.04M
-14.15M
-19.47M
-21.00M
Net interest expenses
-8.25M
-8.28M
-12.96M
-15.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-99.27M
-162.28M
-104.50M
-131.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer